Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 331 to 345 of 983 results for death

  1. Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136)

    Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

    Technology appraisal guidance
    Published
    25 February 2026
    View recommendations

    Sections for TA1136

  2. Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

    Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.

    Technology appraisal guidance
    Published
    2 October 2024
    View recommendations

    Sections for TA1009

  3. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA448

  4. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

    HealthTech guidance
    Published
    26 August 2020
    View recommendations

    Sections for HTG552

  5. Midostaurin for untreated acute myeloid leukaemia (TA523)

    Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA523

  6. Obeticholic acid for treating primary biliary cholangitis (TA443)

    Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA443

  7. Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are antisecretory anti-muscarinic drugs (used alongside nursing interventions, such as repositioning and oropharyngeal suction) better at reducing noisy respiratory secretions and patient, family and carer distress without causing unwanted side effects, than nursing interventions alone?

    respiratory secretions at the end of life and the so called 'death rattle' is a predictor of death. The noise can cause...

    Research recommendation
    Published
    27 January 2016

  8. How you can use our recommendations, tools and resources: maternity and neonatal health

    How to use NICE guidance to reduce health inequalities during and after pregnancy.

  9. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    14 February 2023
    View quality statements

    Sections for QS22

  10. Temperature control to improve neurological outcomes after cardiac arrest (HTG710)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

    HealthTech guidance
    Published
    23 January 2024
    View recommendations

    Sections for HTG710

  11. Deep brain stimulation for refractory epilepsy in adults (HTG550)

    Evidence-based recommendations on deep brain stimulation for refractory epilepsy in adults. This involves implanting an electrical stimulator in the brain.

    HealthTech guidance
    Published
    12 August 2020
    View recommendations

    Sections for HTG550

  12. Irreversible electroporation for treating prostate cancer (HTG688)

    Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.

    HealthTech guidance
    Published
    5 July 2023
    View recommendations

    Sections for HTG688

  13. Percutaneous balloon valvuloplasty for fetal critical aortic stenosis (HTG471)

    Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis. This involves placing a catheter into the baby’s heart, while the baby is still in the womb. The aim is to help the heart develop properly.

    HealthTech guidance
    Published
    9 May 2018
    View recommendations

    Sections for HTG471

  14. Irreversible electroporation for treating renal cancer (HTG303)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG303

  15. Irreversible electroporation for treating primary lung cancer and metastases in the lung (HTG302)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG302